Current Problems in Cancer
Volume 30, Issue 6 , Pages 307-318 , November 2006

Combining Symptom and Survival Data

References 

  1. Goldhirsch A, Gelber RD. Randomized perioperative therapy in operable breast cancer: the Ludwig Trial v. recent results. Cancer Res. 1989;115:43–53
  2. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5:559–575
  3. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics. 1995;7:503–520
  4. Maddigan SL, Feeny DH, Johnson JA DOVE Investigators. Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes. Qual Life Res. 2004;13(2):435–448
  5. Feeny D, Blanchard CM, Mahon JL, Bourne R, Rorabeck C, Stitt L, et al. The stability of utility scores: test-retest reliability and the interpretation of utility scores in elective total hip arthroplasty. Qual Life Res. 2004;13(1):15–22
  6. Feeny D, Furlong W, Saigal S, Sun J. Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons. Soc Sci Med. 2004;58(4):799–809
  7. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–128
  8. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33(5):375–384
  9. Johnson JA, Coons SJ, Ergo A, Szava-Kovats G. Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics. 1998;13:421–433
  10. Kind P. The EuroQOL instrument: an index of health-related quality of life. In:  Spilker B editors. Quality of Life of Pharmacoeconomics in Clinical Trials. (2nd edition).. Philadelphia, PA: Lippincott-Raven Publishers; 1996;p. 191–201
  11. Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC. The “utility” of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol. 1995;48:1207–1214
  12. Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced cancer. J Biopharm Stat. 2004;14(1):111–124
  13. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003;97(12):3053–3060
  14. Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of literature. Med Decis Making. 2005;25(4):460–467
  15. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM, et al. Randomized, surgical adjuvant clinical trial of recombinant Interferon Alfa-2α in selected patients with malignant melanoma. J Clin Oncol. 1995;13(11):2776–2783
  16. Revicki DA, Feeny D, Hunt TL, Cole BF. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res. 2006;15(3):411–423
  17. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET, et al. A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Qual Life Res. 2002;11(1):37–45
  18. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989;7(1):36–44
  19. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomized clinical trials with quality-adjusted survival analysis. Lancet. 2001;358(9278):277–286
  20. Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S French Cooperative CLL Group. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. J Clin Epidemiol. 2001;54(7):747–754
  21. Parsons SK, Gelber S, Cole BF, Ravindranath Y, Ogden A, Yeager AM, et al. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: a Q-TWiST analysis of the Pediatric Oncology Group Study 8821. J Clin Oncol. 1999;17(7):2144–2152
  22. Porcher R, Levy V, Fermand JP, Katsahian S, Chevret S, Ravaud P. Evaluating high dose therapy in multiple myeloma: use of quality-adjusted survival analysis. Qual Life Res. 2002;11(2):91–99
  23. Levy V, Porcher R, Leblond V, Fermand JP, Cazin B, Maloisel F, et al. Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis. Leukemia. 2001;15(9):1466–1470
  24. Mounier N, Ferme C, Flechtner H, Henzy-Amar M, Lepage E. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med Decis Making. 2003;23(1):54–66
  25. Murray S, Cole B. Variance and sample size calculations in quality-of-life-adjusted survival analysis (Q-TWiST). Biometrics. 2000;56(1):173–182
  26. Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality adjusted survival: the Q-TWiST method. Am Stat. 1995;49(2):161–169
  27. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics. 1989;45(3):781–795

PII: S0147-0272(06)00059-6

doi: 10.1016/j.currproblcancer.2006.08.008

Current Problems in Cancer
Volume 30, Issue 6 , Pages 307-318 , November 2006

Article Tools

* Image Usage & Resolution